Related Experiment Videos
Myeloid-derived suppressor cells in gliomas
Anna Gieryng1, Bozena Kaminska1
1Neurobiology Center, Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, PAS, Warsaw, Poland.
Contemporary Oncology (Poznan, Poland)
|April 5, 2017
Summary
Myeloid-derived suppressor cells (MDSCs) expand in high-grade gliomas, hindering anti-tumor immunity. Understanding MDSC roles is crucial for developing effective brain tumor immunotherapies.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Myeloid-derived suppressor cells (MDSCs) are key regulators of immune suppression in cancer.
- High-grade gliomas are aggressive brain tumors with poor prognoses, often associated with an immunosuppressive tumor microenvironment.
Purpose of the Study:
- To review the characteristics and roles of MDSCs in glioma progression.
- To highlight the challenges MDSCs pose to brain tumor immunotherapy.
Main Methods:
- Analysis of histopathology and flow cytometry data from human and rodent gliomas.
- Review of literature on MDSC phenotype, function, and interaction with other immune cells in the glioma microenvironment.
Main Results:
- MDSC infiltration in gliomas correlates with tumor grade and impacts patient survival.
- MDSCs suppress anti-tumor immune responses by inhibiting T cell activation and promoting regulatory T cells.
Conclusions:
- MDSCs are significant contributors to the immunosuppressive glioma microenvironment.
- Targeting MDSCs presents a potential therapeutic strategy for improving glioma immunotherapy outcomes.